CA1202892A - Tumor imaging with radiolabeled monoclonal antibodies - Google Patents

Tumor imaging with radiolabeled monoclonal antibodies

Info

Publication number
CA1202892A
CA1202892A CA000414208A CA414208A CA1202892A CA 1202892 A CA1202892 A CA 1202892A CA 000414208 A CA000414208 A CA 000414208A CA 414208 A CA414208 A CA 414208A CA 1202892 A CA1202892 A CA 1202892A
Authority
CA
Canada
Prior art keywords
antibody
chelating agent
radionuclide
group
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000414208A
Other languages
English (en)
French (fr)
Inventor
Samuel E. Halpern
Gary S. David
Thomas H. Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
University of California
Original Assignee
Hybritech Inc
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc, University of California filed Critical Hybritech Inc
Application granted granted Critical
Publication of CA1202892A publication Critical patent/CA1202892A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA000414208A 1981-10-27 1982-10-26 Tumor imaging with radiolabeled monoclonal antibodies Expired CA1202892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31528681A 1981-10-27 1981-10-27
US315,286 1981-10-27

Publications (1)

Publication Number Publication Date
CA1202892A true CA1202892A (en) 1986-04-08

Family

ID=23223718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000414208A Expired CA1202892A (en) 1981-10-27 1982-10-26 Tumor imaging with radiolabeled monoclonal antibodies

Country Status (18)

Country Link
JP (1) JPS58135820A (no)
AT (1) AT392004B (no)
BE (1) BE894829A (no)
CA (1) CA1202892A (no)
CH (1) CH653040A5 (no)
DE (1) DE3239410A1 (no)
DK (1) DK164682C (no)
ES (2) ES516797A0 (no)
FI (1) FI82379C (no)
FR (1) FR2515046B1 (no)
GB (1) GB2109407B (no)
IL (1) IL67068A0 (no)
IT (1) IT1153857B (no)
LU (1) LU84441A1 (no)
NL (1) NL8204108A (no)
NO (1) NO169947C (no)
SE (1) SE8206073L (no)
ZA (1) ZA827806B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
CA1225930A (en) * 1982-06-07 1987-08-25 Otto A. Gansow Metal chelate conjugated monoclonal antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
GB2139645A (en) * 1983-04-08 1984-11-14 Kureha Chemical Ind Co Ltd Antibody to human prostrate cancer
JPS59199636A (ja) * 1983-04-26 1984-11-12 Nippon Mejifuijitsukusu Kk 放射性診断剤
US4677058A (en) * 1983-05-19 1987-06-30 Karl Tryggvason Detecting malignant cells with monoclonal antibodies specific to type IV collagenase enzyme
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
JPS60201260A (ja) * 1984-03-27 1985-10-11 Yamasa Shoyu Co Ltd 心疾患診断薬
JP2507982B2 (ja) * 1984-04-10 1996-06-19 武田薬品工業株式会社 ヒト癌胎児性抗原反応性モノクロ―ナル抗体の製造法
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
CA1260827A (en) * 1984-08-31 1989-09-26 Richard C. Siegel Antibody-metal ion complexes
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4986256A (en) * 1985-02-28 1991-01-22 The United States Of America As Represented By The Department Of Health And Human Services Use of paramagnetic metalloporphyrins as contrast agents for tumors in MRI imaging
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
US4732974A (en) * 1986-03-05 1988-03-22 Mallinckrodt, Inc. Metal ion labeling of carrier molecules
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5082930A (en) * 1986-05-29 1992-01-21 Mallinckrodt Medical, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4925804A (en) * 1986-06-17 1990-05-15 Baxter International Inc. Interligand metal transfer assay
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
CA1340014C (en) * 1986-10-27 1998-08-25 Bryan Michael Longenecker Carcinoma-marking monoclonal antibodies elicited with synthetic asialo-gmi antigen
US5227474A (en) * 1987-02-13 1993-07-13 Abbott Laboratories Bifunctional chelating agents
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
US5177192A (en) * 1987-04-02 1993-01-05 Centocor, Incorporated Method for labeling antibodies with a metal ion
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US5217704A (en) * 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5648471A (en) * 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5075099A (en) * 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5807535A (en) * 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
US5550160A (en) * 1992-07-31 1996-08-27 Australian Nuclear Science & Technology Organization Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
US7521531B2 (en) 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US6663866B1 (en) 1996-08-28 2003-12-16 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
US6558669B1 (en) 1996-08-28 2003-05-06 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4272503A (en) * 1978-05-25 1981-06-09 New England Nuclear Corporation Reductant composition for technetium-99m and method for making technetium-99m labelled ligands
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
DE3173342D1 (en) * 1980-03-03 1986-02-13 Milton David Goldenberg Agent for tumor localization and therapy with labeled antibodies and antibody fragments

Also Published As

Publication number Publication date
NO823530L (no) 1983-04-28
ZA827806B (en) 1983-08-31
LU84441A1 (fr) 1983-06-13
ES529310A0 (es) 1985-05-16
JPS58135820A (ja) 1983-08-12
SE8206073L (sv) 1983-04-28
IT8223932A0 (it) 1982-10-26
DK474182A (da) 1983-04-28
DK164682B (da) 1992-08-03
ES8505482A1 (es) 1985-05-16
IT1153857B (it) 1987-01-21
NL8204108A (nl) 1983-05-16
FI823633L (fi) 1983-04-28
DE3239410C2 (no) 1991-12-19
FI82379B (fi) 1990-11-30
BE894829A (fr) 1983-02-14
DK164682C (da) 1992-12-21
JPH0564130B2 (no) 1993-09-14
ES8404857A1 (es) 1984-05-16
FR2515046A1 (fr) 1983-04-29
DE3239410A1 (de) 1983-05-19
FI823633A0 (fi) 1982-10-25
FR2515046B1 (fr) 1985-11-29
ES516797A0 (es) 1984-05-16
CH653040A5 (de) 1985-12-13
ATA391682A (de) 1990-07-15
NO169947B (no) 1992-05-18
IL67068A0 (en) 1983-02-23
NO169947C (no) 1992-08-26
GB2109407A (en) 1983-06-02
AT392004B (de) 1991-01-10
SE8206073D0 (sv) 1982-10-26
FI82379C (fi) 1991-03-11
GB2109407B (en) 1985-12-18

Similar Documents

Publication Publication Date Title
CA1202892A (en) Tumor imaging with radiolabeled monoclonal antibodies
US5990286A (en) Antibodies with reduced net positive charge
JP2612454B2 (ja) 親和性増進免疫学試薬
Zalutsky et al. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate intermediate
Goodwin et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12. 5 and 88Y-Janus-2-(p-nitrobenzyl)-1, 4, 7, 10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy
US5153118A (en) Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
JPS635033A (ja) 化合物標的化組成物
IL127193A (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments and use thereof for the prophylaxis and detection of cancers
JPH0647557B2 (ja) 放射性標識抗体フラグメント
Primus et al. Immunological considerations in the use of goat antibodies to carcinoembryonic antigen for the radioimmunodetection of cancer
Gaffar et al. Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon‐specific antigen‐p (CSAp)
EP0228243B1 (en) Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
Ullén et al. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor: nontumor ratio in experimental radioimmunolocalization
KR100485240B1 (ko) 감소된순양전하를갖는항체
Rea et al. Site-specifically radioiodinated antibody for targeting tumors
WO1997025069A9 (en) Antibodies with reduced net positive charge
Gasparini et al. Tumor imaging of colo‐rectal carcinoma with an anti‐CEA monoclonal antibody
Moro The alpha-fetoprotein receptor (RECAF): characterization and potential uses for cancer diagnosis and therapy
Gadina et al. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18
Hansen et al. Labeling of anti-tumor antibodies and antibody fragments with Tc-99m
Pauwels et al. Radiolabelled monoclonal antibodies: A new diagnostic tool in nuclear medicine
Natali et al. Human melanoma associated antigens identified with monoclonal antibodies: characterization and potential clinical application
Nakamura et al. Radioimmunodetection of human pancreatic tumor xenografts using DU-PAN II monoclonal antibody
Lavie et al. Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice
Rogers et al. A monoclonal antibody against a CEA-related antigen expressed on HT29 colon tumour cells

Legal Events

Date Code Title Description
MKEX Expiry